Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Biocartis Raises $15M in Series A Round

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis has raised €10 million ($14.9 million) in a Series A financing round that included a handful of European investment firms.

The Lausanne, Switzerland-based firm is developing a multiplex, molecular diagnostics platform that will be able to quantify and amplify bio-analytes, such as proteins, nucleic acids, and small molecules. The firm said that it will use the proceeds from the private offering to develop a commercial version of its proprietary platform, as well as its first prototype assays.

The Series A round was led by Aescap Ventures, which is based in Amsterdam. Other investors included Biovest (Belgium), KBC Private Equity (Belgium), Advent Venture Partners (UK), and Benaruca (Luxembourg). Each of the investors has a representative on Biocartis' board of directors.

Biocartis was founded in 2007. It was founded by its President, Rudi Pauwels, who previously co-founded Tibotec, Virco, and Galapagos Genomics.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.